191 related articles for article (PubMed ID: 28434401)
1. Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety.
Chaccour C; Hammann F; Rabinovich NR
Malar J; 2017 Apr; 16(1):161. PubMed ID: 28434401
[TBL] [Abstract][Full Text] [Related]
2. A Roadmap for the Development of Ivermectin as a Complementary Malaria Vector Control Tool.
; Billingsley P; Binka F; Chaccour C; Foy B; Gold S; Gonzalez-Silva M; Jacobson J; Jagoe G; Jones C; Kachur P; Kobylinski K; Last A; Lavery JV; Mabey D; Mboera D; Mbogo C; Mendez-Lopez A; Rabinovich NR; Rees S; Richards F; Rist C; Rockwood J; Ruiz-Castillo P; Sattabongkot J; Saute F; Slater H; Steer A; Xia K; Zullinger R
Am J Trop Med Hyg; 2020 Feb; 102(2s):3-24. PubMed ID: 31971144
[TBL] [Abstract][Full Text] [Related]
3. Incidental mosquitocidal effect of an ivermectin mass drug administration on Anopheles farauti conducted for scabies control in the Solomon Islands.
Kositz C; Talina J; Diau J; Asugeni R; Whitehorn C; Mabey D; Chaccour C; Marks M
Trans R Soc Trop Med Hyg; 2017 Mar; 111(3):97-101. PubMed ID: 28549173
[TBL] [Abstract][Full Text] [Related]
4. Differential susceptibilities of Anopheles albimanus and Anopheles stephensi mosquitoes to ivermectin.
Dreyer SM; Morin KJ; Vaughan JA
Malar J; 2018 Apr; 17(1):148. PubMed ID: 29615055
[TBL] [Abstract][Full Text] [Related]
5. Ivermectin as a novel malaria control tool: Getting ahead of the resistance curse.
Sagna AB; Zéla L; Ouedraogo COW; Pooda SH; Porciani A; Furnival-Adams J; Lado P; Somé AF; Pennetier C; Chaccour CJ; Dabiré RK; Mouline K
Acta Trop; 2023 Sep; 245():106973. PubMed ID: 37352998
[TBL] [Abstract][Full Text] [Related]
6. Screening for an ivermectin slow-release formulation suitable for malaria vector control.
Chaccour C; Barrio Á; Gil Royo AG; Martinez Urbistondo D; Slater H; Hammann F; Del Pozo JL
Malar J; 2015 Mar; 14():102. PubMed ID: 25872986
[TBL] [Abstract][Full Text] [Related]
7. Lethal and sublethal impacts of membrane-fed ivermectin are concentration dependent in Anopheles coluzzii.
Shepherd-Gorringe MAM; Pettit MW; Hawkes FM
Parasit Vectors; 2024 May; 17(1):228. PubMed ID: 38755640
[TBL] [Abstract][Full Text] [Related]
8. The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors.
Kobylinski KC; Deus KM; Butters MP; Hongyu T; Gray M; da Silva IM; Sylla M; Foy BD
Acta Trop; 2010 Nov; 116(2):119-26. PubMed ID: 20540931
[TBL] [Abstract][Full Text] [Related]
9. Impact of ivermectin components on Anopheles dirus and Anopheles minimus mosquito survival.
Khemrattrakool P; Hongsuwong T; Tipthara P; Kullasakboonsri R; Phanphoowong T; Sriwichai P; Hanboonkunupakarn B; Jittamala P; Tarning J; Kobylinski KC
Parasit Vectors; 2024 May; 17(1):224. PubMed ID: 38750608
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ivermectin and its metabolites against
Annamalai Subramani P; Tipthara P; Kolli SK; Nicholas J; Barnes SJ; Ogbondah MM; Kobylinski KC; Tarning J; Adams JH
Antimicrob Agents Chemother; 2024 Jun; ():e0127223. PubMed ID: 38904389
[TBL] [Abstract][Full Text] [Related]
11. Current Use of Ivermectin in Dermatology, Tropical Medicine, and COVID-19: An Update on Pharmacology, Uses, Proven and Varied Proposed Mechanistic Action.
Mathachan SR; Sardana K; Khurana A
Indian Dermatol Online J; 2021; 12(4):500-514. PubMed ID: 34430453
[TBL] [Abstract][Full Text] [Related]
12. Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway.
Chaccour C; Rabinovich NR
Malar J; 2017 Apr; 16(1):166. PubMed ID: 28434405
[TBL] [Abstract][Full Text] [Related]
13. Ivermectin to reduce malaria transmission III. Considerations regarding regulatory and policy pathways.
Chaccour C; Rabinovich NR
Malar J; 2017 Apr; 16(1):162. PubMed ID: 28434407
[TBL] [Abstract][Full Text] [Related]
14. Ivermectin and malaria control.
Ōmura S; Crump A
Malar J; 2017 Apr; 16(1):172. PubMed ID: 28438169
[TBL] [Abstract][Full Text] [Related]
15. Upon entering an age of global ivermectin-based integrated mass drug administration for neglected tropical diseases and malaria.
Richards FO
Malar J; 2017 Apr; 16(1):168. PubMed ID: 28438168
[TBL] [Abstract][Full Text] [Related]
16. Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis.
Nicolas P; Maia MF; Bassat Q; Kobylinski KC; Monteiro W; Rabinovich NR; Menéndez C; Bardají A; Chaccour C
Lancet Glob Health; 2020 Jan; 8(1):e92-e100. PubMed ID: 31839144
[TBL] [Abstract][Full Text] [Related]
17. Ivermectin for causal malaria prophylaxis: a randomised controlled human infection trial.
Metzger WG; Theurer A; Pfleiderer A; Molnar Z; Maihöfer-Braatting D; Bissinger AL; Sulyok Z; Köhler C; Egger-Adam D; Lalremruata A; Esen M; Lee Sim K; Hoffman S; Rabinovich R; Chaccour C; Alonso P; Mordmüller BG; Kremsner PG
Trop Med Int Health; 2020 Mar; 25(3):380-386. PubMed ID: 31808594
[TBL] [Abstract][Full Text] [Related]
18. Ivermectin: From theory to clinical application.
Ashour DS
Int J Antimicrob Agents; 2019 Aug; 54(2):134-142. PubMed ID: 31071469
[TBL] [Abstract][Full Text] [Related]
19. Safety of high-dose ivermectin: a systematic review and meta-analysis.
Navarro M; Camprubí D; Requena-Méndez A; Buonfrate D; Giorli G; Kamgno J; Gardon J; Boussinesq M; Muñoz J; Krolewiecki A
J Antimicrob Chemother; 2020 Apr; 75(4):827-834. PubMed ID: 31960060
[TBL] [Abstract][Full Text] [Related]
20. Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers.
Muñoz J; Ballester MR; Antonijoan RM; Gich I; Rodríguez M; Colli E; Gold S; Krolewiecki AJ
PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006020. PubMed ID: 29346388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
